Davis Polk is advising Roche in connection with its $230 million acquisition of Anadys Pharmaceuticals, Inc. In accordance with the terms of the merger agreement entered into by the parties, Roche will commence a tender offer for all of the outstanding shares of Anadys at $3.70 per share in cash. The closing of the transaction is expected to take place in 2011.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused health care with combined strengths in pharmaceuticals and diagnostics. San Diego, California-based Anadys develops oral, small molecule therapeutics for the potential treatment of hepatitis C virus infection. 

The Davis Polk team includes partners Arthur F. Golden and Marc O. Williams, associates Carson T. Stewart and Livingston A. Miller and foreign temporary associate Robyn Butler (not yet admitted). Partner Jean M. McLoughlin and associate Jennifer Freiman are providing employee benefits advice. Partner Michael Mollerus is providing tax advice. Associate David R. Bauer is providing intellectual property advice. All members of the Davis Polk team are based in the New York office.